New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
10:49 EDTICE, NYX, BRK.ANYSE received counter-bid with value below ICE offer, reportedly from Berkshire
In a regulatory filing this morning, IntercontinentalExchange (ICE) disclosed that during the run-up to its agreement to merge with NYSE Euronext (NYX), NYSE's advisers initiated contact with representatives of a large industrial and financial holding company, identified in the filing as “Company A,” that they believed would be interested in NYSE Euronext’s businesses. Company A presented an indicative proposal with a value lower than the ICE proposal, according to the filing, and Company A's proposal also required that NYSE Euronext must first sell its European derivatives business for a specified minimum price. According to CNBC's David Faber, Company A described in the filing is Berkshire Hathaway (BRK.A). In the filing, IntercontinentalExchange also said the agreed upon merger with NYSE is subject to the merger control jurisdiction of the national competition authorities in Portugal, Spain and the U.K. The companies stated they intend to request a referral of the merger to the European Commission, such that merger clearance is required from only the European Commission in the EU. ICE and NYSE expect to submit the notification form to the European Commission during the first half of 2013, the filing said. In morning trading, NYSE Euronext shares were virtually unchanged, while IntercontinentalExchange was up 18c, or 0.13%, to $135.00.
News For A From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
07:23 EDTAAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
05:29 EDTADako announces FDA approval of new companion diagnostic assay
Subscribe for More Information
October 2, 2015
15:57 EDTALabCorp to offer PD-L1 companion diagnostic
Subscribe for More Information
15:43 EDTAQuest Diagnostics introduces Dako's PD-L1 companion diagnostic for KEYTRUDA
Subscribe for More Information
15:25 EDTAAgilent's Dako confirms FDA approval of NSCLC diagnostic
Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced the FDA approval of a new companion diagnostic assay that can reveal whether a patient with advanced non-small cell lung cancer, or NSCLC, is likely to respond to a new form of treatment. The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako's portfolio of companion diagnostics and the company's leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck (MRK), maker of the anti-PD-1 therapy Keytruda. The FDA approved PD-L1 IHC 22C3 pharmDx for use in the United States. Dako hopes to gain regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.
September 24, 2015
17:04 EDTAMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use